NCT07204392 Unveiling the Germline Predisposition to Myeloproliferative Neoplasms
| NCT ID | NCT07204392 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Condition | Myeloproliferative Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 313 participants |
| Start Date | 2022-06-27 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 313 participants in total. It began in 2022-06-27 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The classic Ph-negative myeloproliferative neoplasms (MPN) are a group of clonal hematopoietic disorders caused by a dysregulated JAK/STAT signal transduction because of acquired somatic mutations of JAK2, CALR or MPL genes. They are sporadic diseases but there are several lines of evidence that support the role of germline factors in the pathogenesis of MPN: the existence of familial clustering, the presence of more than one clone in some patients, the known existence of common polymorphisms that cause predisposition to MPN. In this study, we would like to define the germline predisposition to MPN.
Eligibility Criteria
Inclusion Criteria: * A diagnosis of PV, ET, prePMF, overt PMF or MPN-U according to 2016 WHO criteria * Characterization of the MPN driver mutation performed at any moment before enrolment * diagnosis of MPN made when the patient was younger than 27 years old OR at least a second case of hematologic malignancies in first or second-degree relatives Exclusion Criteria: * None
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07204392 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloproliferative Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07204392 currently recruiting?
Yes, NCT07204392 is actively recruiting participants. Contact the research team at e.rumi@smatteo.pv.it for enrollment information.
Where is the NCT07204392 trial being conducted?
This trial is being conducted at Pavia, Italy.
Who is sponsoring the NCT07204392 clinical trial?
NCT07204392 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. The trial plans to enroll 313 participants.